

TORRENT PHARMACEUTICALS LIMITED

PART I	[Rs. in Lacs except per share data]			
Statement of Standalone Audited Results for the Quarter Ended 30-Jun-2012				
Particulars	Quarter ended			Year ended
	30-Jun-2012	31-Mar-2012	30-Jun-2011	31-Mar-2012
Income from operations				
Net sales (Net of excise duty) (see note 2)	62011	52657	47802	198669
Other operating income	2899	1802	2881	8935
Total income from operations (net)	64910	54459	50683	207604
Expenses				
Cost of materials consumed	17606	14749	14739	59017
Purchases of stock-in-trade	11992	8329	2911	25210
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(4879)	515	(368)	(3596)
Employee benefits expense	8803	7868	7753	30905
Depreciation and amortisation expense	1632	1676	1468	6390
Other expenses	17022	16484	11937	56029
Total expenses	52176	49621	38440	173955
Profit from operations before other income, finance costs and exceptional items	12734	4838	12243	33649
Other income	5790	9925	1286	13519
Profit from ordinary activities before finance costs and exceptional items	18524	14763	13529	47168
Finance costs	1043	936	1020	3978
Profit from ordinary activities after finance costs but before exceptional items	17481	13827	12509	43190
Exceptional items	-	6120	-	6120
Profit from ordinary activities before tax	17481	7707	12509	37070
Tax expense	2729	(300)	2565	5945
Net profit for the period	14752	8007	9944	31125
Paid-up equity share capital (Face value of Rs.5 each)	4231	4231	4231	4231
Reserves excluding revaluation reserves	-	-	-	126218
Earnings per share (of Rs. 5/- each) (not annualised):				
Basic	17.44	9.46	11.75	36.79
Diluted	17.44	9.46	11.75	36.79

PART II				
Select Information for the Quarter Ended 30-Jun-2012				
PARTICULARS OF SHAREHOLDING	Quarter ended			Year ended
	30-Jun-2012	31-Mar-2012	30-Jun-2011	31-Mar-2012
Public shareholding				
- Number of shares	24109500	24109500	24109500	24109500
- Percentage of shareholding	28.49%	28.49%	28.49%	28.49%
Promoters and Promoter group Shareholding				
a) Pledged/Encumbered				
- Number of shares	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil
b) Non-encumbered				
- Number of shares	60501860	60501860	60501860	60501860
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the company)	71.51%	71.51%	71.51%	71.51%
INVESTOR COMPLAINTS	Quarter ended			
	30-Jun-2012			
Pending at the beginning of the quarter	Nil			
Received during the quarter	Nil			
Disposed of during the quarter	Nil			
Remaining unresolved at the end of the quarter	Nil			

Notes:

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors, in their respective meetings held on 23-July-2012. There is no qualification in the Auditors Report on this statement of financial results.
- 2 The Company operates a solitary business segment viz. pharmaceuticals, comprising mainly manufacture of branded formulations. A further breakdown of pharmaceutical sales is given below.

[Rs. in Lacs]

Particulars	Quarter ended			Year ended
	30-Jun-2012	30-Jun-2011	Growth %	31-Mar-2012
(A) Sales in India				
Branded sales	28023	24643	14%	91670
Contract manufacture	4751	6133	(23%)	24271
Others	351	123	-	1472
Total sales in India	33125	30899	7%	117413
(B) Sales outside India	29057	16997	71%	81736
Total sales (A+B)	62182	47896	30%	199149
Less:Excise duty	171	94	-	480
Net sales	62011	47802	30%	198669

- 3 During the current quarter, the Company made additional investment of Rs. 1520 lacs, in equity shares of its wholly owned subsidiary, Zao Torrent Pharma.
- 4 The Company has also prepared and published unaudited consolidated financial results for the quarter ended 30-Jun-2012, which were subjected to limited review by statutory auditors of the Company.

For TORRENT PHARMACEUTICALS LIMITED

Place : Ahmedabad
Date : 23-Jul-2012

sd/-
SAMIR MEHTA
Executive Vice Chairman

.... Visit us at www.torrentpharma.com....